These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21547706)

  • 21. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
    Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
    Mehta N; Dodge JL; Grab JD; Yao FY
    Hepatology; 2020 Mar; 71(3):943-954. PubMed ID: 31344273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation.
    Teng F; Wang GH; Tao YF; Guo WY; Wang ZX; Ding GS; Shi XM; Fu ZR
    World J Gastroenterol; 2014 Aug; 20(31):10900-7. PubMed ID: 25152592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients.
    Akbulut S; Kayaalp C; Yilmaz M; Ince V; Ozgor D; Karabulut K; Eris C; Toprak HI; Aydin C; Yilmaz S
    World J Gastroenterol; 2013 Mar; 19(10):1625-31. PubMed ID: 23538988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HCC in living donor liver transplantation: can we expand the Milan criteria?
    Kwon CH; Kim DJ; Han YS; Park JB; Choi GS; Kim SJ; Joh JW; Lee SK
    Dig Dis; 2007; 25(4):313-9. PubMed ID: 17960066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-fetoprotein and
    Yang Z; Luo FZ; Wang S; Lerut J; Zhuang L; Li QY; Xu X; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):229-234. PubMed ID: 32303439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Living donor liver transplantation for hepatocellular carcinoma.
    Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
    Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation.
    Onaca N; Davis GL; Goldstein RM; Jennings LW; Klintmalm GB
    Liver Transpl; 2007 Mar; 13(3):391-9. PubMed ID: 17318865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
    Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
    Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
    JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
    Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
    Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria.
    Bhangui P; Saigal S; Gautam D; Piplani T; Choudhary N; Chaudhary R; Yadav S; Thiagarajan S; Rastogi A; Saraf N; Nundy S; Soin AS
    Liver Transpl; 2021 Feb; 27(2):209-221. PubMed ID: 33253492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
    An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
    Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.
    Toso C; Asthana S; Bigam DL; Shapiro AM; Kneteman NM
    Hepatology; 2009 Mar; 49(3):832-8. PubMed ID: 19152426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.